argenex SE $ARGX Shares Purchased by M&T Bank Corp

M&T Bank Corp boosted its stake in argenex SE (NASDAQ:ARGX) by 20,977.7% in the 4th quarter, Holdings Channel reports. The firm owned 778,610 shares of the company’s stock after purchasing an additional 774,916 shares during the period. argenex comprises about 1.9% of M&T Bank Corp’s portfolio, making the stock its 8th largest holding. M&T Bank Corp’s holdings in argenex were worth $654,772,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Abound Wealth Management increased its holdings in argenex by 3,200.0% in the 4th quarter. Abound Wealth Management now owns 33 shares of the company’s stock valued at $28,000 after purchasing an additional 32 shares during the last quarter. Sound Income Strategies LLC acquired a new stake in argenex in the 4th quarter valued at approximately $28,000. Ameriflex Group Inc. acquired a new stake in argenex in the 3rd quarter valued at approximately $32,000. Aventura Private Wealth LLC acquired a new stake in argenex in the 4th quarter valued at approximately $38,000. Finally, Sunbelt Securities Inc. acquired a new position in shares of argenex in the third quarter worth $36,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ARGX. Wedbush reissued an “outperform” rating and set a $1,000.00 target price on shares of argenex in a research note on Monday, March 9th. HC Wainwright boosted their target price on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Wells Fargo & Company lowered their target price on argenex from $1,317.00 to $1,247.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Citizens Jmp boosted their target price on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a research note on Friday, February 27th. Finally, Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,016.22.

argenex Price Performance

Shares of ARGX opened at $805.38 on Wednesday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The stock has a market cap of $50.09 billion, a PE ratio of 41.26, a price-to-earnings-growth ratio of 1.37 and a beta of 0.46. The firm has a fifty day moving average price of $765.72 and a 200 day moving average price of $819.14.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Saturday, February 14th. The company reported $8.02 earnings per share for the quarter. argenex had a net margin of 30.42% and a return on equity of 38.51%. As a group, equities analysts expect that argenex SE will post 24.61 EPS for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.